Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Front Oncol
2013 Aug 05;3:195. doi: 10.3389/fonc.2013.00195.
Show Gene links
Show Anatomy links
Targeting genomic alterations in squamous cell lung cancer.
Mantripragada K
,
Khurshid H
.
Abstract
Squamous cell lung cancer causes approximately 400,000 deaths worldwide per year. Identification of specific molecular alterations, such as activating mutations in the epidermal growth factor receptor kinase and echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase fusions have led to significant therapeutic gains in patients with adenocarcinoma. However, meaningful therapeutic gains based on the molecular pathobiology of squamous cell lung cancer have not yet been realized. A comprehensive genomic characterization of 178 cases of squamous cell lung cancer has recently been reported. Squamous cell lung cancer appears to be characterized by a broader and more complex group of genomic alterations than adenocarcinoma. In this review, potentially targetable genes or pathways in squamous cell lung cancer are emphasized in relation to available therapeutic agents in development or active clinical trials. This organization of data will provide a framework for development for clinical investigation. Squamous cell lung cancer appears to be characterized by not only driver mutations in candidate genes but also gene copy number alterations resulting in tumor proliferation and survival. Better understanding of these genetic alterations and their use as therapeutic targets will require broad collaboration between industry, government, the cooperative groups, and academic institutions with the ultimate goal of rapid translation of scientific advancement to patient benefit.
Andjelković,
Role of translocation in the activation and function of protein kinase B.
1997, Pubmed
Andjelković,
Role of translocation in the activation and function of protein kinase B.
1997,
Pubmed
Bass,
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
2009,
Pubmed
Bellacosa,
Akt activation by growth factors is a multiple-step process: the role of the PH domain.
1998,
Pubmed
Bendell,
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
2012,
Pubmed
Benedettini,
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
2010,
Pubmed
Benvenuti,
The MET receptor tyrosine kinase in invasion and metastasis.
2007,
Pubmed
Birchmeier,
Met, metastasis, motility and more.
2003,
Pubmed
Brannan,
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
2009,
Pubmed
Bussolino,
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.
1992,
Pubmed
Cai,
Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.
2011,
Pubmed
Cancer Genome Atlas Research Network,
Comprehensive genomic characterization of squamous cell lung cancers.
2012,
Pubmed
Cappuzzo,
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
2009,
Pubmed
Carpten,
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
2007,
Pubmed
Chang,
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
2008,
Pubmed
Cooper,
Molecular cloning of a new transforming gene from a chemically transformed human cell line.
NULL,
Pubmed
Davidson,
Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.
2010,
Pubmed
Day,
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
2008,
Pubmed
Do,
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting.
2008,
Pubmed
Dutt,
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.
2011,
Pubmed
Engelman,
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
2006,
Pubmed
Faoro,
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
2010,
Pubmed
Felip,
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
2011,
Pubmed
Fukuoka,
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
2011,
Pubmed
Furge,
Met receptor tyrosine kinase: enhanced signaling through adapter proteins.
2000,
Pubmed
Garraway,
Lineage dependency and lineage-survival oncogenes in human cancer.
2006,
Pubmed
Ghaffar,
LKB1 protein expression in the evolution of glandular neoplasia of the lung.
2003,
Pubmed
Giordano,
The semaphorin 4D receptor controls invasive growth by coupling with Met.
2002,
Pubmed
Gontan,
Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation.
2008,
Pubmed
Guagnano,
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
2012,
Pubmed
Göke,
Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
2012,
Pubmed
Hammerman,
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
2011,
Pubmed
Haura,
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
2010,
Pubmed
Hussenet,
SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.
2010,
Pubmed
Ichikawa,
Structural basis of the collagen-binding mode of discoidin domain receptor 2.
2007,
Pubmed
Ji,
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
2011,
Pubmed
Ji,
LKB1 modulates lung cancer differentiation and metastasis.
2007,
Pubmed
Jin,
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
2010,
Pubmed
Ju,
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
2012,
Pubmed
Kawano,
PIK3CA mutation status in Japanese lung cancer patients.
2006,
Pubmed
Khurshid,
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.
2012,
Pubmed
Knobbe,
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
2003,
Pubmed
Kong-Beltran,
Somatic mutations lead to an oncogenic deletion of met in lung cancer.
2006,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
2010,
Pubmed
Li,
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
1997,
Pubmed
Lombardo,
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
2004,
Pubmed
Lu,
Evidence that SOX2 overexpression is oncogenic in the lung.
2010,
Pubmed
Lutterbach,
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
2007,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Malanga,
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
2008,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Morgensztern,
Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.
2009,
Pubmed
Neshat,
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
2001,
Pubmed
Okudela,
PIK3CA mutation and amplification in human lung cancer.
2007,
Pubmed
Ou,
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
2011,
Pubmed
Pao,
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
2004,
Pubmed
Pasquale,
Eph receptor signalling casts a wide net on cell behaviour.
2005,
Pubmed
Que,
Multiple roles for Sox2 in the developing and adult mouse trachea.
2009,
Pubmed
Rekhtman,
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
2012,
Pubmed
Rong,
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.
1994,
Pubmed
Rosell,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
2012,
Pubmed
Rubin,
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.
1991,
Pubmed
Ruiz,
Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts.
2011,
Pubmed
Schmidt,
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
1997,
Pubmed
Seo,
The transcriptional landscape and mutational profile of lung adenocarcinoma.
2012,
Pubmed
Sequist,
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
2011,
Pubmed
Shah,
LKB1 and lung cancer: more than the usual suspects.
2008,
Pubmed
Shaw,
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
2011,
Pubmed
Sholl,
Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas.
2010,
Pubmed
Siegel,
Cancer statistics, 2013.
2013,
Pubmed
Sos,
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
2009,
Pubmed
Spoerke,
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
2012,
Pubmed
Stokoe,
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B.
1997,
Pubmed
Sun,
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
2010,
Pubmed
Turner,
A therapeutic target for smoking-associated lung cancer.
2010,
Pubmed
Vanhaesebroeck,
The PI3K-PDK1 connection: more than just a road to PKB.
2000,
Pubmed
Vivanco,
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
2002,
Pubmed
Vogel,
Sensing extracellular matrix: an update on discoidin domain receptor function.
2006,
Pubmed
Weiss,
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
2010,
Pubmed
Yamamoto,
PIK3CA mutations and copy number gains in human lung cancers.
2008,
Pubmed
Zhou,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
2011,
Pubmed
Zou,
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
2009,
Pubmed